SupraSense
Financiado
Development of Suprasensors and Assays for Molecular Diagnostics
SupraSense combines completely new strategies to design and realize biomimetic artificial receptors for bioactive small molecules, i.e. metabolites, with the aim of overcoming long-standing selectivity and sensitivity limitations...
SupraSense combines completely new strategies to design and realize biomimetic artificial receptors for bioactive small molecules, i.e. metabolites, with the aim of overcoming long-standing selectivity and sensitivity limitations that hindered other synthetic sensory systems from reaching diagnostic applications. Sophisticated yet easy to fabricate SupraSensors will be developed based on unprecedented hybrid zeolitic materials whose binding cavities are modulated by peptide-based cofactors, thereby mimicking enzyme pockets. SupraSensors will be functional and directly applicable for molecular diagnostics in urine, saliva, and blood and will be of utility in point-of-care units and personal homes. Emphasis is given to the detection of metabolites that are important disease indicators.
I am an expert on conventional synthetic chemosensors and have studied both their merits and fundamental shortcomings. Out of this deep routed analysis, I developed the proposed ambitious strategy that marries principles of molecular recognition with materials science and chemistry-informed deep learning. These SupraSensors will advance the field through the following elements: i) high-energy water release from microporous materials ensures high binding affinity; ii) strategically placed peptide-based recognition elements provide selectivity while offering synthetic tunability; iii) information-rich signal output from SupraSensor libraries enables metabolite distinction in biofluids; iv) novel signal amplification concepts increase sensitivity. SupraSensor discovery will be fast and generalizable to many metabolite classes.
SupraSense has the potential to unleash supreme opportunities for multiparameter diagnostics, which will be essential for patient subgrouping based on metabolic phenotypes. The new concepts developed herein have the prospect to revolutionize early detection of emerging cardiovascular events, inflammations, sepsis, and other metabolic or aging-associated diseases.
ver más
Duración del proyecto: 61 meses
Fecha Inicio: 2023-05-09
Fecha Fin: 2028-06-30
Fecha Fin: 2028-06-30
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-05-09
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2022-COG:
ERC CONSOLIDATOR GRANTS
Cerrada
hace 2 años
Presupuesto
El presupuesto total del proyecto asciende a
2M€
Líder del proyecto
KARLSRUHER INSTITUT FUER TECHNOLOGIE
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5